example #30 (S) [WO2014210255A1]

Ligand id: 10464

Name: example #30 (S) [WO2014210255A1]

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 79.19
Molecular weight 297.15
XLogP 1.86
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
4-[(3S)-1-prop-2-enoylpiperidin-3-yl]-1H-indole-7-carboxamide
Synonyms
elsubrutinib (proposed INN)
Comments
This compound is the (S) stereoenantiomer of example #30 from Abbvie's patent WO2014210255A1 which claims BTK inhibitors and their potential to treat immunological and oncological conditions [1]. This chemical structure matches the IUPAC name that was submitted to the WHO for the INN elsubrutinib (INN proposed list 121 of August 2019). Example #30 (S) could be ABBV-105, an Abbvie BTK inhibitor that is being evaluated in combination with upadacitinib (ABT-494, a JAK1 inhibitor) in patients with rheumatoid arthritis or systemic lupus erythematosus (the combination is coded ABBV-599). Although preclinical efficacy has been reported [2], the structure of ABBV-105 has not been formally disclosed, so the name-to-structure alluded to here is speculative.
Database Links
CAS Registry No. 1643570-24-4 (source: WHO INN record)
GtoPdb PubChem SID 385612224
PubChem CID 117773770
Search Google for chemical match using the InChIKey UNHZLHSLZZWMNP-LLVKDONJSA-N
Search Google for chemicals with the same backbone UNHZLHSLZZWMNP
Search UniChem for chemical match using the InChIKey UNHZLHSLZZWMNP-LLVKDONJSA-N
Search UniChem for chemicals with the same backbone UNHZLHSLZZWMNP